Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment firm Citadel Group has disclosed a 1.54% stake in Mural Oncology plc, according to a regulatory filing published Friday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 267,332 shares in the biopharmaceutical company, representing approximately 1.54% of Mural’s outstanding common stock. This includes 253,932 shares owned or controlled directly and 13,400 shares through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 1.11% of Mural’s shares, primarily through stock-settled derivatives including options.
The position was reported as of September 25, 2025, and includes details of multiple transactions executed on that date. These transactions involved both purchases and sales of common shares at prices ranging from $2.09 to $2.10 per share.
The disclosure includes information about Citadel’s options positions, with various call and put options expiring between October 2025 and January 2027, with strike prices ranging from $2.50 to $7.50.
Irish takeover rules require investors to disclose positions when they hold interests in relevant securities representing 1% or more of a company’s shares.
The information was provided through a Form 8.3 filing with the Irish Takeover Panel, which requires disclosure of interests in companies that may be involved in takeover situations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.